Cargando…
Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
Rifaximin, a non-absorbable antibiotic, has been demonstrated to be effective against hepatic encephalopathy (HE); however, its efficacy on liver functional reserve remains unknown. Here, we evaluated the efficacy of rifaximin on the liver functional reserve and serological inflammation-based marker...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054398/ https://www.ncbi.nlm.nih.gov/pubmed/36983211 http://dx.doi.org/10.3390/jcm12062210 |
_version_ | 1785015661181796352 |
---|---|
author | Kitsugi, Kensuke Kawata, Kazuhito Noritake, Hidenao Chida, Takeshi Ohta, Kazuyoshi Ito, Jun Takatori, Shingo Yamashita, Maho Hanaoka, Tomohiko Umemura, Masahiro Matsumoto, Moe Suda, Takafumi |
author_facet | Kitsugi, Kensuke Kawata, Kazuhito Noritake, Hidenao Chida, Takeshi Ohta, Kazuyoshi Ito, Jun Takatori, Shingo Yamashita, Maho Hanaoka, Tomohiko Umemura, Masahiro Matsumoto, Moe Suda, Takafumi |
author_sort | Kitsugi, Kensuke |
collection | PubMed |
description | Rifaximin, a non-absorbable antibiotic, has been demonstrated to be effective against hepatic encephalopathy (HE); however, its efficacy on liver functional reserve remains unknown. Here, we evaluated the efficacy of rifaximin on the liver functional reserve and serological inflammation-based markers in patients with cirrhosis. A retrospective study was conducted on patients who received rifaximin for more than three months at our hospital between November 2016 and October 2021. The recurrence and grade of HE, serological ammonia levels, Child–Pugh score (CPS), and serological inflammation-based markers such as the neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), platelet–lymphocyte ratio (PLR), C-reactive protein (CRP), and CRP to albumin ratio (CAR) were evaluated. The correlations between serological inflammation-based markers and liver functional reserve were evaluated. HE grades, serum ammonia levels, and inflammation-based markers significantly improved at three months compared with those at baseline. Patients with improved albumin levels showed significantly higher CRP improvement rates at both 3 and 12 months. Patients with an improvement in CAR at 3 months demonstrated a significant improvement in CPS at 12 months. Rifaximin improved the liver functional reserve in patients with cirrhosis. Improvements in inflammation-based markers, particularly CRP and albumin, may be involved in this process. |
format | Online Article Text |
id | pubmed-10054398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100543982023-03-30 Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation Kitsugi, Kensuke Kawata, Kazuhito Noritake, Hidenao Chida, Takeshi Ohta, Kazuyoshi Ito, Jun Takatori, Shingo Yamashita, Maho Hanaoka, Tomohiko Umemura, Masahiro Matsumoto, Moe Suda, Takafumi J Clin Med Article Rifaximin, a non-absorbable antibiotic, has been demonstrated to be effective against hepatic encephalopathy (HE); however, its efficacy on liver functional reserve remains unknown. Here, we evaluated the efficacy of rifaximin on the liver functional reserve and serological inflammation-based markers in patients with cirrhosis. A retrospective study was conducted on patients who received rifaximin for more than three months at our hospital between November 2016 and October 2021. The recurrence and grade of HE, serological ammonia levels, Child–Pugh score (CPS), and serological inflammation-based markers such as the neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), platelet–lymphocyte ratio (PLR), C-reactive protein (CRP), and CRP to albumin ratio (CAR) were evaluated. The correlations between serological inflammation-based markers and liver functional reserve were evaluated. HE grades, serum ammonia levels, and inflammation-based markers significantly improved at three months compared with those at baseline. Patients with improved albumin levels showed significantly higher CRP improvement rates at both 3 and 12 months. Patients with an improvement in CAR at 3 months demonstrated a significant improvement in CPS at 12 months. Rifaximin improved the liver functional reserve in patients with cirrhosis. Improvements in inflammation-based markers, particularly CRP and albumin, may be involved in this process. MDPI 2023-03-13 /pmc/articles/PMC10054398/ /pubmed/36983211 http://dx.doi.org/10.3390/jcm12062210 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kitsugi, Kensuke Kawata, Kazuhito Noritake, Hidenao Chida, Takeshi Ohta, Kazuyoshi Ito, Jun Takatori, Shingo Yamashita, Maho Hanaoka, Tomohiko Umemura, Masahiro Matsumoto, Moe Suda, Takafumi Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation |
title | Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation |
title_full | Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation |
title_fullStr | Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation |
title_full_unstemmed | Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation |
title_short | Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation |
title_sort | rifaximin improves liver functional reserve by regulating systemic inflammation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054398/ https://www.ncbi.nlm.nih.gov/pubmed/36983211 http://dx.doi.org/10.3390/jcm12062210 |
work_keys_str_mv | AT kitsugikensuke rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT kawatakazuhito rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT noritakehidenao rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT chidatakeshi rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT ohtakazuyoshi rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT itojun rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT takatorishingo rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT yamashitamaho rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT hanaokatomohiko rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT umemuramasahiro rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT matsumotomoe rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation AT sudatakafumi rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation |